15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 13 firms covering Madrigal Pharmaceuticals Inc, 12 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets span $542.00 to $962.00, a moderate spread. The average target of $693.67 sits 30% above the current $533.71. The rating mix has stayed broadly stable, with Buy-side ratings easing from 13 to 12 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.42 next quarter toward $9.63 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS13 ratings
Strong Buy
Strong Buy00%
Buy1292%
Hold18%
Sell00%
Strong Sell00%
Based on 13 analysts giving stock ratings to Madrigal Pharmaceuticals Inc.
As of Sep, 12 of 13 firms rate MDGL a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
MDGL EPS & revenue forecast
EPS · NEXT QUARTER
$-0.42
Range $-0.77 – $0.11 · 4 analysts · -84% YoY
Next period, 4 analysts expect Madrigal Pharmaceuticals Inc to earn $-0.42 a share (range $-0.77 – $0.11), versus $-2.57 a year earlier. Full-year consensus is $-6.49, growing to $9.63 the year after.
REVENUE · NEXT QUARTER
$444.7M
Range $418.5M – $478.0M · 4 analysts · +39% YoY
Revenue is expected to reach $444.7M (range $418.5M – $478.0M), +38.5% year-over-year. Full-year consensus is $1.5B, rising to $2.1B next year.
Top analysts covering Madrigal Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on MDGL.
#1
Jonathan Wolleben
JMP Securities · Rank #29
Buy
$739.00+38.5% to target
Overall win rate
47%
+ Follow
#2
Mayank Mamtani
B. Riley Securities · Rank #41
Buy
$560.00+4.9% to target
Overall win rate
50%
+ Follow
#3
Andrew Fein
HC Wainwright & Co. · Rank #55
Buy
$620.00+16.2% to target
Overall win rate
46%
+ Follow
#4
Yasmeen Rahimi
Piper Sandler · Rank #188
Buy
$900.00+68.6% to target
Overall win rate
33%
+ Follow
#5
Jay Olson
Oppenheimer · Rank #360
Buy
$650.00+21.8% to target
Overall win rate
33%
+ Follow
MDGL stock forecast FAQ
What is MDGL's average 12-month price target?+
The 12 analysts with a live target average $693.67 for Madrigal Pharmaceuticals Inc over the next 12 months, ranging from a $962.00 high to a $542.00 low.
Is MDGL stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 13 analyst ratings, 12 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for MDGL?+
The Street-high target is $962.00 (Barclays), and the Street-low is $542.00 (B of A Securities). The average of all 12 active targets is $693.67.
How many Wall Street analysts cover MDGL?+
13 analysts have an active rating on Madrigal Pharmaceuticals Inc, and 12 firms carry a live 12-month price target.
Who is the most accurate analyst covering MDGL?+
Among analysts who currently cover MDGL, Jonathan Wolleben of JMP Securities has the strongest overall Quantellect track record (Rank #29). Their current call is Buy with a $739.00 target.
What is Madrigal Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $-0.42 per share (range $-0.77 – $0.11) across 4 analysts. Full-year EPS is projected at $-6.49, rising to $9.63 the following year.
How much revenue is Madrigal Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $444.7M (range $418.5M – $478.0M). Full-year revenue is projected at $1.5B, growing to $2.1B next year.
Have analysts been upgrading or downgrading MDGL lately?+
As of Sep, 12 of 13 firms rate MDGL a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their MDGL calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
